Published in Cancer Weekly, December 1st, 2009
"All participants were asked to complete hot flash diaries. reporting weekly hot flash scores > 15 during baseline week underwent a 1-week single-blind placebo run-in. Those reporting hot flash score reductions > 50% following placebo run-in were excluded. The remaining women received an assigned treatment for 4 weeks. Both groups' demographic and clinical characteristics were similar with a greater decline, but not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.